Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

SV Life Sciences leads Juvaris's $25mm Series B

Executive Summary

Juvaris BioTherapeutics (adjuvant vaccines for infectious diseases) announced its $25mm Series B financing round led by first-time backer SV Life Sciences, which was joined by returning shareholder Kleiner Perkins Caufield & Byers. The company will use the money to continue developing its platform of cationic-lipid DNA complexes, including lead clinical candidate JVRS100 for seasonal and pandemic influenza. A member of SV Life Sciences takes a seat on the board.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies